Carregant...

IMMU-63. OVERCOMING GLIOBLASTOMA RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE VIA RNA-LOADED NANOPARTICLES

BACKGROUND: In a randomized phase III study for recurrent glioblastoma (GBM), checkpoint inhibition with nivolumab failed to improve overall survival outcomes. GBM immune escape through loss of MHC class expression juxtaposed to an immunoregulatory milieu, both local and systemic, remain significant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Sayour, Elias, Grippin, Adam, Mendez-Gomez, Hector, De Leon, Gabriel, Mitchell, Duane
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692051/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.520
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!